Journey Colab

Journey Colab is using psychedelic medicines to develop a new form of addiction treatment that couples the promise of neuroplasticity-promoting therapeutics with psychotherapy and social support.

The company's main development focus is synthetic Mescaline HCl for persons with alcohol use disorder (AUD), who require long-term relief from this persistent, relapsing illness.

Journey Colab has a distinct stakeholder organization to build an experienced team devoted to their goal of developing scientifically rigorous and clinically validated treatments and expanding equitable access to care.

Psychedelic News

Journey Colab Announces Appointment of Joel A. Posener, MD as Chief Medical Officer

Biopharmaceutical company Journey Colab who are working to unlock the science of psychedelics and build a new model for addiction treatment recently

July 20, 2022

Journey Colab

Journey Colab Announces Appointment of Joel A. Posener, MD as Chief Medical Officer

Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment

Numinus Develop Psilocybin Mushroom Tea Bags for Psychedelic Research Use

atai Life Sciences Announce First Subject Dosed in Synthetic DMT Phase 1 Trial

Suggestions

Journey Colab

Journey Colab Announces Appointment of Joel A. Posener, MD as Chief Medical Officer

Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment

Numinus Develop Psilocybin Mushroom Tea Bags for Psychedelic Research Use

atai Life Sciences Announce First Subject Dosed in Synthetic DMT Phase 1 Trial